Anti-phospholipid antibodies restore mesenteric ischemia/reperfusion-induced injury in complement receptor 2/complement receptor 1-deficient mice

J Immunol. 2004 Dec 1;173(11):7055-61. doi: 10.4049/jimmunol.173.11.7055.

Abstract

Complement receptor 2-deficient (Cr2(-/-)) mice are resistant to mesenteric ischemia/reperfusion (I/R) injury because they lack a component of the natural Ab repertoire. Neither the nature of the Abs that are involved in I/R injury nor the composition of the target Ag, to which recognition is lacking in Cr2(-/-) mice, is known. Because anti-phospholipid Abs have been shown to mediate fetal growth retardation and loss when injected into pregnant mice, we performed experiments to determine whether anti-phospholipid Abs can also reconstitute I/R injury and, therefore, represent members of the injury-inducing repertoire that is missing in Cr2(-/-) mice. We demonstrate that both murine and human monoclonal and polyclonal Abs against negatively charged phospholipids can reconstitute mesenteric I/R-induced intestinal and lung tissue damage in Cr2(-/-) mice. In addition, Abs against beta2 glycoprotein I restore local and remote tissue damage in the Cr2(-/-) mice. Unlike Cr2(-/-) mice, reconstitution of I/R tissue damage in the injury-resistant Rag-1(-/-) mouse required the infusion of both anti-beta2-glycoprotein I and anti-phospholipid Ab. We conclude that anti-phospholipid Abs can bind to tissues subjected to I/R insult and mediate tissue damage.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Antibodies, Anticardiolipin / administration & dosage
  • Antibodies, Anticardiolipin / therapeutic use
  • Antibodies, Antiphospholipid / administration & dosage
  • Antibodies, Antiphospholipid / metabolism
  • Antibodies, Antiphospholipid / therapeutic use*
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / metabolism
  • Antibodies, Monoclonal / therapeutic use
  • Female
  • Glycoproteins / immunology
  • Glycoproteins / metabolism
  • Homeodomain Proteins / genetics
  • Humans
  • Immune Sera / administration & dosage
  • Infusions, Intravenous
  • Intestinal Mucosa / blood supply*
  • Intestinal Mucosa / immunology*
  • Intestinal Mucosa / pathology
  • Lung / immunology
  • Lung / pathology
  • Male
  • Mesenteric Arteries*
  • Mice
  • Mice, Knockout
  • Receptors, Complement 3b / deficiency*
  • Receptors, Complement 3b / genetics
  • Receptors, Complement 3b / physiology
  • Receptors, Complement 3d / deficiency*
  • Receptors, Complement 3d / genetics
  • Receptors, Complement 3d / physiology
  • Reperfusion Injury / genetics
  • Reperfusion Injury / immunology*
  • Reperfusion Injury / prevention & control*
  • beta 2-Glycoprotein I

Substances

  • Antibodies, Anticardiolipin
  • Antibodies, Antiphospholipid
  • Antibodies, Monoclonal
  • Glycoproteins
  • Homeodomain Proteins
  • Immune Sera
  • Receptors, Complement 3b
  • Receptors, Complement 3d
  • beta 2-Glycoprotein I
  • RAG-1 protein